- Net income jumps more than fourfold to $14.1B, or $1.98 a share, boosted by the spinoff of Pfizer's (PFE) Zoetis animal-health unit and a patent settlement with Teva and Sun Pharmaceutical over Pfizer's Protonix acid reflux medicine.
- Raises FY reported EPS forecast to $3.07-3.22 from a prior forecast of $1.44-1.59, reflecting the gain from Zoetis and the patent deal.
- Reiterates adjusted EPS guidance of $2.10-2.20 vs consesnus of $2.16 and revenue of $50.8-52.8B vs $51.83B. (PR)
More on Pfizer Q2: Net income jumps more than fourfold
Jul 30 2013, 04:52 ET